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Abstract
Background: HIV-infected persons with detectable cryptococcal antigen (CrAg) in blood have increased morbidity
and mortality compared with HIV-infected persons who are CrAg-negative. This study examined neurocognitive
function among persons with asymptomatic cryptococcal antigenemia.
Methods: Participants from three prospective HIV cohorts underwent neurocognitive testing at the time of
antiretroviral therapy (ART) initiation. Cohorts included persons with cryptococcal meningitis (N = 90), asymptomatic
CrAg + (N = 87), and HIV-infected persons without central nervous system infection (N = 125). Z-scores for each
neurocognitive test were calculated relative to an HIV-negative Ugandan population with a composite quantitative
neurocognitive performance Z-score (QNPZ-8) created from eight tested domains. Neurocognitive function was
measured pre-ART for all three cohorts and additionally after 4 weeks of ART (and 6 weeks of pre-emptive
fluconazole) treatment among asymptomatic CrAg + participants.
Results: Cryptococcal meningitis and asymptomatic CrAg + participants had lower median CD4 counts (17 and 26
cells/μL, respectively) than the HIV-infected control cohort (233 cells/μL) as well as lower Karnofsky performance
status (60 and 70 vs. 90, respectively). The composite QNPZ-8 for asymptomatic CrAg + (−1.80 Z-score) fell between
the cryptococcal meningitis cohort (−2.22 Z-score, P = 0.02) and HIV-infected controls (−1.36, P = 0.003). After four
weeks of ART and six weeks of fluconazole, the asymptomatic CrAg + cohort neurocognitive performance
improved (−1.0 Z-score, P < 0.001).
Conclusion: Significant deficits in neurocognitive function were identified in asymptomatic CrAg + persons with
advanced HIV/AIDS even without signs or sequelae of meningitis. Neurocognitive function in this group improves over
time after initiation of pre-emptive fluconazole treatment and ART, but short term adherence support may be necessary.
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Background
Cryptococcal meningitis is one of the leading causes of
death from HIV/AIDS in sub-Saharan Africa [1, 2] causing
15–20% of AIDS-related mortality [3]. In the United
States, cryptococcal meningitis is more common than all
causes of bacterial meningitis combined (1.1 vs. 0.73 per
100,000 people, respectively) [4, 5]. Yet cryptococcal
disease is potentially preventable as cryptococcal antigen
(CrAg) is detectable in the peripheral blood weeks to
months prior to the onset of symptomatic meningitis.
Although many of these CrAg + persons exhibit no
clinical signs or symptoms despite the presence of early
disseminated infection, CrAg + persons have increased
risk of developing meningitis or death compared to HIV-
infected persons without cryptococcal antigenemia [6–9].
The World Health Organization (WHO) and U.S. HIV
guidelines recommend routine CrAg screening for HIV-
infected persons with <100 CD4 T cells/μL who are not
receiving effective antiretroviral therapy (ART), along
with pre-emptive fluconazole therapy for those screening
CrAg + [10, 11]. Despite these recommendations, many
gaps remain in understanding the morbidity and clinical
course of asymptomatic CrAg + persons.
Persons living with HIV, regardless of their CrAg serosta-
tus, have increased risk of neurocognitive deficits, presum-
ably through the direct toxic effect of the HIV virus itself
and consequent inflammation. The wide array of observed
disorders is referred to collectively as HIV-associated neu-
rocognitive disorder (HAND), which ranges from mild cog-
nitive impairment to the more extreme HIV-associated
dementia [12]. One prevalence study estimated that 31% of
people living with HIV in Uganda have HIV dementia and
that people with older age and lower CD4 counts are at
higher risk [13].
Opportunistic infections of the central nervous system
(CNS) create potential for further damage, and HIV-
infected persons with cryptococcal meningitis, specifically,
are known to have increased neurocognitive deficits com-
pared with their HIV-infected, CrAg-negative peers [14, 15].
It is not known whether cryptococcal antigenemia increases
the risk of neurocognitive dysfunction in asymptomatic
CrAg + persons, which may have an implication for
additional needed support for general HIV care. The
purpose of this study was to 1) investigate neurocognitive
changes among HIV-infected persons with asymptomatic
cryptococcal antigenemia, and 2) compare neurocognitive
performance of these asymptomatic CrAg + persons to
HIV-infected persons with cryptococcal meningitis and
those without CNS infection.
Methods
This study utilized three cohorts of HIV-infected ART-
naïve persons enrolled in prospective clinical trials and co-
hort studies in Kampala, Uganda. All participants provided
written, informed consent prior to enrollment. Studies were
approved by institutional review boards in Uganda and
Minnesota.
Study populations
The first population consisted of HIV-infected persons
hospitalized with cryptococcal meningitis who survived to
the one-month follow-up visit. These participants were
prospectively enrolled into a clinical trial to determine opti-
mal timing of ART after the first episode of cryptococcal
meningitis (ClinicalTrials.gov: NCT01075152) [14, 16].
Cryptococcal meningitis was diagnosed based on cerebro-
spinal fluid (CSF) culture and/or CSF CrAg lateral flow
assay (Immy, Norman, Oklahoma). Participants diagnosed
with cryptococcal meningitis were treated with combined
amphotericin B deoxycholate (0.7–1.0 mg/kg/day) plus
fluconazole 800 mg/day in a two-week induction therapy
regimen, followed by enhanced consolidation therapy of
fluconazole of 800 mg/day for ~3 weeks, then 400 mg/
day for 8 weeks, and then secondary prophylaxis with
fluconazole 200 mg/day. ART was initiated at either 1–
2 weeks following cryptococcal meningitis diagnosis or
5 weeks after diagnosis, based on the randomized trial
arm in the main clinical trial. Baseline neurocognitive
testing was performed at approximately 1 month after
meningitis diagnosis. We have previously shown that
there was no difference in baseline or longitudinal
neurocognitive function based on early vs. deferred ART.
Additional study details have been published previously
[14, 16].
The second study population included HIV-infected,
ART-naïve persons who were CrAg + in plasma after lab-
based reflexive screening among persons with CD4 < 100
cells/μL, but without symptoms of cryptococcal meningi-
tis (ClinicalTrials.gov: NCT01535469). Participants were
enrolled prospectively and followed for 6 months. All
asymptomatic CrAg + persons received pre-emptive
fluconazole therapy at 400 mg twice daily for 2 weeks,
followed by 400 mg daily for the subsequent 8 weeks.
ART was started 2 weeks after initiation of flucona-
zole. Neurocognitive testing was performed at the
ART initiation visit and then again 4 weeks after
ART initiation.
Third, to account for the potential effect of HAND, we
included a population of HIV-infected persons enrolled in
an outpatient clinic setting [17]. HIV-infected adults were
screened consecutively for enrollment, and those with
clinical signs or symptoms of meningitis or with a history of
CNS infection were excluded. Additional exclusion criteria
included active psychiatric disease, alcoholism, or physical
deficits that would interfere with neurocognitive testing. In
this cohort, neurocognitive testing was performed once
prior to ART initiation.
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Neurocognitive testing
Participants in all three cohorts underwent outpatient
neurocognitive testing with a neuropsychological battery
of tests. Testing for all three cohorts and for the retesting
of the asymptomatic CrAg + cohort was performed by the
same team using the same study forms and was conducted
in participant’s native language. The assessments explored
the following neurocognitive domains: Attention span:
Digit Span Forward and Backward [18] and Color Trails 1
[19]. Processing speed: Digit Symbol test [18] and Color
Trails 1 [19]. Executive function: Color Trails 2 [19]. Ver-
bal learning: WHO-UCLA (University of California, Los
Angeles) Auditory Verbal Learning Test-Revised [20].
Language fluency: Semantic Verbal Fluency [21]. Motor
speed: Finger Tapping [22]. Fine motor skills: Grooved
Pegboard [23]. Additional file 1 provides a description of
each of these tests. Each test score was compared with a
standard reference population of HIV-negative Ugandans
matched on age and education to produce an age and
education adjusted Z-score [24, 25]. Negative Z-scores in-
dicate a worse performance compared with the reference
population. A composite score using all eight tests was
calculated to create a Quantitative Neurological Perform-
ance Z-score (QNPZ-8 score) [26].
In addition to neurocognitive testing, all three populations
were evaluated for functional status with the Karnofsky per-
formance status scale [27]. Participants were screened for
dementia using the International HIV Dementia Scale
(IHDS) [24]. Total scores range from 0 to 12 with a score ≤ 10
being 80% sensitive and 55% specific for HIV dementia. De-
pression was assessed using the Center for Epidemiologic
Studies Depression (CES-D) Scale [28], which ranges from 0
to 60. Higher scores correspond with increased chance of
depression, and a score of 16 or greater has good sensitivity
and specificity for identifying clinical depression [29, 30]. All
enrolled participants who completed baseline neurocognitive
testing were included in the analyses.
Data analysis
Data were analyzed using STATA/IC version 9.2
(StataCorp, College Station, TX, USA) and are available
online in a supplemental file (Additional file 2). Partici-
pants who initiated the neurocognitive tests but were too
sick to complete all tests attempted as many neurocogni-
tive tests as possible and skipped the remainder. For each
skipped/uncompleted test, participants were assigned a
value of −2 standard deviations below the cohort mean for
that test, as has been done previously [14]. Comparisons
of variables among populations were made using unpaired
Student’s t-tests, Mann-Whitney U tests, and chi-square
tests as appropriate. Linear regression was used to identify
factors associated with QNPZ-8 score. Comparisons of
neurocognitive performance over time were made using
paired t-tests of Z-scores.
Results
Participants with asymptomatic cryptococcemia were
slightly younger in age (median 31 years, interquartile range
(IQR): 27–39 years) compared with participants with
cryptococcal meningitis (36 years, IQR: 30–40) and HIV-
infected controls (37, IQR: 32–41) (Table 1). There were
significantly more women in the HIV control population
(68% women) relative to patients with Cryptococcus infec-
tion. Median education level ranged from 7 to 8 years in
the three groups. CD4 count, Karnofsky score, CES-D scale,
and IHDS were variable among the three groups. Partici-
pants with cryptococcal meningitis had the lowest median
CD4 count (17 cells/μL, IQR: 7–79), the lowest median
Karnofsky score (60, IQR: 50–70), the highest proportion of
participants with IHDS < =10 (92%), and the highest me-
dian scores for depression (CES-D: 23, IQR: 16–30). At the
other end of the spectrum, the HIV-infected controls had
the lowest proportion with IHDS < =10 (66%), the lowest
depression scale scores (CES-D: 9, IQR: 5–17), highest
Karnofsky performance score (90, IQR: 90–90), and signifi-
cantly higher median CD4 counts (233 cells/μL, IQR: 183–
297) compared with the other two study populations.
Overall, asymptomatic CrAg + participants fell in between
the two populations and were notably more similar to
cryptococcal meningitis survivors with regard to CD4 count
(median 26 cells/μL, IQR: 9–59).
Individual pre-ART neurocognitive test Z-scores for each
population are displayed in Fig. 1 (see Additional file 3).
Asymptomatic CrAg + persons performed significantly
worse than HIV-infected controls in every domain except
for the Color Trails 1 and Grooved Pegboard tests. In
addition, asymptomatic CrAg + persons did not signifi-
cantly differ from cryptococcal meningitis survivors in any
measure except for the Grooved Pegboard and Color Trails
1 tests (i.e., domains of speed of information processing, at-
tention, fine motor). With respect to the composite QNPZ-
8 score, the three study populations were significantly dif-
ferent from each other, with cryptococcal meningitis survi-
vors performing the worst (QNPZ-8 = −2.22 vs −1.80
among asymptomatic CrAg+, P = 0.02) and HIV-infected
controls performing the best (QNPZ-8 = −1.36, P = 0.003
compared with asymptomatic CrAg+).
There were slight demographic and other variable differ-
ences across the three cohort groups, thus a multiple linear
regression analysis was performed to assess for independent
risk factors associated with decreased neurocognitive
performance (Table 2). In an adjusted multivariable model,
the QNPZ-8 scores for HIV-infected controls remained
significantly higher than QNPZ-8 scores for asymptomatic
CrAg + persons (QNPZ-8: +0.42, 95% confidence interval
(CI): 0.03 to 0.81). The asymptomatic CrAg + persons did
not statistically differ from persons with recent cryptococcal
meningitis (QNPZ-8: -0.26, 95% CI: -0.59 to 0.07). For each
10 year-increase in age, participants’ QNPZ-8 decreased by
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−0.31 (95% CI: -0.48 to −0.15), and participants with CES-
D depression scores ≥16 had a mean difference of −0.56
QNPZ-8 score (95% CI: -0.82 to −0.30). In the multivariable
model, CD4 count was not significantly associated with
neurocognitive function after adjusting for study cohort
(QNPZ-8 = 0.02 per 100 CD4 cells/μL, 95% CI: -0.10 to
0.14; P = 0.79). Baseline pre-ART plasma CrAg titer was
also not associated with QNPZ-8 score among the
CrAg + and cryptococcal meningitis cohorts (P = 0.41, data
not shown).
Lastly, we examined neurocognitive performance among
asymptomatic CrAg + persons over time, comparing the
pre-ART time point after 2 weeks of fluconazole and a
time after 6 weeks of fluconazole plus 4 weeks of ART
(Table 3). All measures showed significant improvement
after 4 weeks of ART, except for Digit Span Forward,
which tests the domains of working memory and atten-
tion. The overall QNPZ-8 score improved in the first 4
weeks of ART by +0.7 standard deviations of the popula-
tion (P < 0.001). The baseline characteristics for asymp-
tomatic CrAg + persons also improved significantly over 4
weeks. Average CD4 count increased from 32 cells/μL to
80 cells/μL (P < 0.001) and average depression scores
decreased from 19 to 16 (P = 0.04). Mean Karnofsky
performance scores modestly increased from 72 to 75 out
of a 100-point scale (P = 0.04), indicating that participants
on average were able to care for themselves but unable to
carry on normal activity or to do active work.
Discussion
In this analysis of HIV-infected persons, we found that
asymptomatic cryptococcal antigenemia is associated with
more neurocognitive deficits compared with HIV-infected
persons without a history of CNS infection. On several mea-
sures of neurocognitive function, HIV-infected CrAg + per-
sons did not differ significantly from survivors of
cryptococcal meningitis who were tested at 1 month after
meningitis diagnosis [14]. Secondly, longitudinal assessment
of asymptomatic CrAg + persons found that they had sig-
nificant improvement in neurocognitive function on most
neurocognitive measures after the first 4 weeks of ART.
These findings have important practical implications.
Table 1 Background and clinical characteristics of three study populations
Cohort A Cohort B Cohort C
Cryptococcal meningitis (N = 90) Asymptomatic CRAG+ (N = 87) HIV+ controls (N = 125)
N % or
Median
(IQR) N % or
Median
(IQR) N % or
Median




Age (years) 90 36 (30–40) 87 31 (27–39) 125 37 (32–41) 0.02 <0.001
Sex 90 87 125
Male 60% 51% 32%
Female 40% 49% 68% 0.21 0.007
Education level (years) 90 8 (4–11) 87 7 (3–11) 125 8 (6–11) 0.15 0.05
< 7 years 36% 45% 27%
7 to 12 years 51% 44% 62%
> 12 years 13% 11% 10% 0.45 0.02
CD4 count (cells/uL) 79 17 (7–79) 86 26 (9–59) 125 233 (183–297) 0.93 <0.001
Karnofsky score 90 60 (50–70) 87 70 (60–80) 125 90 (90–90) <0.001 <0.001
40 1% 0% 0%
50 28% 11% 0%
60 36% 20% 1%
70 29% 26% 0%
80 3% 29% 2%
90 3% 14% 97%
International HIV dementia scale 88 87 125
< =10 92% 75% 66%
> 10 8% 25% 34% 0.002 0.20
CES depression scale 88 23 (16–30) 87 18 (10–26) 125 9 (5–17) 0.007 <0.001
< 16 25% 41% 70%
> =16 75% 59% 30% 0.02 <0.001
Twenty participants from the cryptococcal meningitis cohort and 28 asymptomatic CrAg + participants were excluded due to insufficient data to calculate a
QNPZ-8 score. P-values were calculated from student’s T-test (comparing means), Mann-Whitney U test, and chi-square test as appropriate
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Persons with very advanced AIDS with asymptomatic
cryptococcal antigenemia or recent history of cryptococcal
meningitis have substantial neurocognitive dysfunction with
severe deficits in executive function, verbal learning, and
speed of information processing. With their neurocognitive
dysfunction, this group of cryptococcal survivors and
asymptomatic CrAg + persons likely require additional sup-
port to initially manage their ART and HIV care in order to
avoid poor ART outcomes.
There are several potential explanations for the observa-
tion that asymptomatic CrAg + persons perform worse
than HIV-infected persons without cryptococcal infection.
Initial exposure to Cryptococcus is through the respiratory
system, and the development of antigenemia results from
dissemination from the respiratory system to the blood
stream [31]. The course of disease seen thereafter is variable
in time course, and asymptomatic CrAg + persons likely
form a spectrum of infection – from those without any
CNS penetration of Cryptococcus to persons with subclin-
ical cryptococcal infection of the brain and meninges. More
advanced HIV states are likely to result in increased CSF
inflammation, which may increase risk of neurocognitive
Table 2 Simple and multiple linear regression analyses estimating the relationship of patient characteristics with composite
neurocognitive function, QNPZ-8 score








Cryptococcal meningitis (N = 90) −0.42 (−0.74, −0.09) 0.01 −0.26 (−0.59, 0.07) 0.12
Asymptomatic CRAG (N = 87) Referent - - Referent - -
HIV positive controls (N = 125) 0.44 (0.14, 0.74) 0.004 0.42 (0.03, 0.81) 0.04
Age (per 10 years) 302 −0.20 (−0.37, −0.03) 0.02 −0.31 (−0.48, −0.15) <0.001
Gender (Men as referent group) 302 0.01 (−0.25, 0.27) 0.94 −0.21 (−0.47, 0.04) 0.11
CD4 count (per 100 increase) 290 0.16 (0.07, 0.26) 0.001 0.02 (−0.10, 0.14) 0.79
Depressionb 300 −0.77 (−1.02, −0.53) <0.001 −0.56 (−0.82, −0.30) <0.001
aEach estimate corresponds with the change in QNPZ-8 score for each incremental change in the variable
bDepression modeled as a binary variable comparing using CES-D score > = 16 versus <16 as referent
Fig. 1 Neurocognitive test Z-scores according CrAg status. SDM – Symbol digit modalities. GPB, D – Grooved pegboard, dominant hand. GPB, ND –
Grooved pegboard, non-dominant hand. DSF – Digit span forward. DSB – Digit span backward. AVL – Auditory visual learning. QNPZ-8 – Quantitative
neurological performance Z-score on 8 modalities. Error bars indicate +/− one standard error. The number of imputed scores for each study ranged
from 2 to 41 for CrAg + with meningitis, 1–34 for CrAg + asymptomatic, and 0–2 for HIV+ controls. Imputed scores for persons who started but could
not complete a neurocognitive test were two standard deviations the group mean for the test. Numbers represent Z-scores referenced against age
and education adjusted, HIV-negative Ugandan population norms. * < .05 ** < .0001
Montgomery et al. BMC Neurology  (2017) 17:110 Page 5 of 9
impairment or HAND [12]. Thus, the decreased cognitive
function in asymptomatic CrAg + persons could be ex-
plained, at least in part, by increased prevalence of HAND.
One could similarly postulate that asymptomatic
CrAg + persons perform poorly on neurocognitive testing
because they have more advanced HIV with lower CD4
counts and functional performance. After adjusting for
CD4 count, the CrAg + cohort effect remained while the
effect of CD4 disappeared. This is most likely the result of
“aggregation bias” wherein the cohort is too intricately
related to the CD4 count to make a valid comparison.
Unfortunately, there was an insufficient number of partici-
pants in the HIV+ control group with CD4 < 100 (N = 15)
to perform an adequate subset analysis. Ideally, future
studies should be conducted comparing asymptomatic
CrAg + persons to CrAg-negative persons with similar
CD4 counts. CSF sampling was not performed in the
asymptomatic cohort. Some asymptomatic persons would
have had detectable CSF CrAg and others would have had
Cryptococcus yeasts in the brain parenchyma in the ab-
sence of CSF CrAg detectability. However, the fundamen-
tal conclusion remains that cryptococcal antigenemia in
persons with low CD4 counts, even if not a causal factor
for neurocognitive impairment, can be a useful marker for
identifying persons with decreased neurocognitive func-
tion. This has very important implications when enrolling
these persons into HIV treatment and care as there is
likely a need for increased adherence support for these
persons compared to the typical HIV-infected person
initiating HIV care.
The second finding of the study demonstrated that asymp-
tomatic CrAg + persons improved on most neurocognitive
measures over a period of 4 weeks. In our prior longitudinal
follow-up of persons with cryptococcal meningitis, neurocog-
nitive performance came to within one standard deviation of
HIV-negative population norms (QNPZ-8 = −1.0 ± 1.1) and
similar to HIV-infected controls (QNPZ-8 = −0.7 ± 1.0) after
12 months [14]. Thus, we would expect the majority of
CrAg + persons to normalize their neurocognitive function
over time on ART [32, 33], and any additional adherence
and/or social support required is likely of short duration.
One additional contributing factor that should be consid-
ered is practice effect, especially given the one-month inter-
val between evaluations. Practice effect has been identified
in previous cohorts of HIV-infected persons undergoing
neurocognitive testing [17, 34]. Comparing longitudinal
changes in neurocognitive performance in both the study
and the control populations would be beneficial. Unfortu-
nately, repeat testing of neurocognitive function in our
HIV-infected control population was not performed. Aside
from practice effect, it is important to note that participants
demonstrated improved Karnofsky performance status over
the first month of ART (P = 0.04). The improvement in
neurocognitive function is therefore potentially explained
by ART initiation with improved control of HIV infection
and/or the use of pre-emptive fluconazole therapy.
There are several limitations in this study that should be
considered. HIV viral load was not measured in either
plasma or CSF, which may act as a potential confounder
for worse neurocognitive function, although plasma levels
Table 3 Population characteristics and average neurocognitive test Z-scores for 73 persons with asymptomatic cryptococcal antigenemia
Pre-ART visit week 2
of fluconazole
Week 4 of HIV therapy week 6
of fluconazole
Intra-person change
Population Characteristics Average SD Average SD Change SD P-value
CD4 count (cells/uL), N = 60 32 ±30 80 ±74 47 ±66 <0.001
Karnofsky score, N = 73 72 ±12 75 ±11 2.5 ±10 0.04
CES depression scale, N = 73 19 ±10 16 ±10 −3.0 ±12 0.04
Neurocognitive Tests
Symbol digit modalities −1.9 ±1.2 −1.5 ±1.5 0.4 ±1.0 0.002
Grooved pegboard dominant −0.3 ±1.3 0.1 ±1.1 0.4 ±1.4 0.02
Grooved pegboard non-dominant −0.4 ±1.5 -0.02 ±1.3 0.3 ±1.3 0.03
Color Trails 1 −2.4 ±2.6 −1.0 ±1.7 1.4 ±2.3 <0.001
Color Trails 2 −3.7 ±2.6 −1.9 ±1.6 1.7 ±2.1 <0.001
Digit span forward −0.5 ±0.9 −0.3 ±0.9 0.2 ±0.9 0.15
Digit span backward −1.4 ±1.4 −1.1 ±1.3 0.3 ±1.2 0.03
Auditory verbal learning −2.2 ±1.4 −1.2 ±1.5 1.0 ±1.2 <0.001
Verbal fluency −0.9 ±0.7 −0.6 ±0.7 0.3 ±0.7 0.005
Finger tapping −2.3 ±1.1 −1.9 ±1.0 0.4 ±1.1 0.002
QNPZ-8 -1.7 ±1.0 −1.0 ±0.8 0.7 ±0.7 <0.001
Numbers represent Z-scores referenced against age and education adjusted, HIV-negative Ugandan population norms. Initial testing was performed at the pre-ART
visit which was 2 weeks after diagnosis of cryptococcal antigenemia and receipt of fluconazole pre-emptive therapy. Statistical testing by paired t-test
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would be expected to be high [35]. In the prior crypto-
coccal meningitis cohort, the pre-ART plasma HIV viral
load was not associated with neurocognitive dysfunction
[14]. Secondly, the repeat testing of neurocognitive function
which showed improvement after 1 month of ART may
have a component of improvement due to a practice effect,
but overall appears quite promising for longer term func-
tion. As shown previously among cryptococcal meningitis
survivors, their neurocognitive function normalizes to within
one standard deviation of population norms within 1 year of
ART [14]. Additionally, although meningitis was excluded in
the HIV-infected control population, this population was
not tested for CrAg. Based on a median CD4 of 233 cells/
μL, there may have been approximately 3 of 100 controls
who could have tested positive, and in sensitivity analyses,
this was not enough to account for the findings [8].
Conclusions
In summary, asymptomatic CrAg + persons have worse
neurocognitive function compared with their HIV-
infected peers without CNS infection, although the exact
etiology of poor neurocognitive function is unclear. There
are a multitude of reasons for starting pre-emptive flucon-
azole treatment in HIV-infected CrAg + persons in the
absence of meningitis. Screening is cost effective, and
pre-emptive treatment with fluconazole can prevent
cryptococcal meningitis and reduce early ART mortality
[36]. Additional support for ART and fluconazole adher-
ence during the first month of therapy has been associated
with improved mortality [37]. As more countries roll out
CrAg screening in populations with advanced HIV, some
initial adherence support may be necessary due to the
neurocognitive dysfunction present in CrAg + persons.
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